Methods and interventions
Each participant in the CPA/EE + Met group took 0.5 g metformin 3 times per day and one tablet of CPA/EE consisting of 2 mg cyproterone acetate and 35-μg ethinylestradiol, per day (starting on the first day of each menstrual cycle for 21 consecutive days and then pausing for 7 days) for 12 weeks. Each participant in the GLP-1RA + Met group took 0.5 g metformin 3 times per day, liraglutide was administered subcutaneously at a dose of 0.6 mg once daily and increased to 1.2 mg/day after one week, with a maximum dose of 1.8 mg/day, Pregnancy is not allowed throughout the treatment.